Chart - CYP, page-45

"MEND was only ever a COVID-19 bandwagon vehicle to attract funding. They didn't think about spreading the risk."

I see that statement of yours as a theory about management Sigma - but one for which you don't provide evidence just a conclusion.

I've been reading through the CYP announcements to see if CYPs interest in covid is real - and I'm more inclined to think it might be real - genuine - something that management might be trying to further in the spirit of making the most of the changed situation. The investor presentation announcement of 10 June is probably worth more of a read than the quick skim I gave it. It shows that ARDS, sepsis and CRS are aspects of COVID-19 in some cases. It also says they are looking to extend the trial to other jurisdictions.

I still need to read more (including to understand what is involved in clinical trials here in Australia and elsewhere in the world) but think your theory on managements motives re MEND is not supported properly by evidence.

--- unrelated to the above - it would be nuts and I hope management are not countenancing any takeovers at this time because it would take their eye of the ball of getting runs on the board to build up inherent value to a point where a future takeover offer would be for more than $2.